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Abstract
Background: High grade gliomas (HGGs; grades III and IV) are the most common primary brain tumors in adults,
and their malignant nature ranks them fourth in incidence of cancer death. Standard treatment for glioblastomas
(GBM), involving surgical resection followed by radiation and chemotherapy with temozolomide (TMZ) and the
anti-angiogenic therapy bevacizumab, have not substantially improved overall survival. New therapeutic agents
are desperately needed for this devastating disease. Here we study the potential therapeutic agent AG119 in a
pre-clinical model for gliomas. AG119 possesses both anti-angiogenic (RTK inhibition) and antimicrotubule
cytotoxic activity in a single molecule.
Methods: GL261 glioma-bearing mice were either treated with AG119, anti-VEGF (vascular endothelial growth
factor) antibody, anti c-Met antibody or TMZ, and compared to untreated tumor-bearing mice. Animal survival
was assessed, and tumor volumes and vascular alterations were monitored with morphological magnetic
resonance imaging (MRI) and perfusion-weighted imaging, respectively.
Results: Percent survival of GL261 HGG-bearing mice treated with AG119 was significantly higher (p < 0.001)
compared to untreated tumors. Tumor volumes (21–31 days following intracerebral implantation of GL261 cells)
were found to be significantly lower for AG119 (p < 0.001), anti-VEGF (p < 0.05) and anti-c-Met (p < 0.001)
antibody treatments, and TMZ-treated (p < 0.05) mice, compared to untreated controls. Perfusion data indicated
that both AG119 and TMZ were able to reduce the effect of decreasing perfusion rates significantly (p < 0.05 for
both), when compared to untreated tumors. It was also found that IC50 values for AG119 were much lower than
those for TMZ in T98G and U251 cells.
Conclusions: These data support further exploration of the anticancer activity AG119 in HGG, as this compound
was able to increase animal survival and decrease tumor volumes in a mouse GL261 glioma model, and that
AG119 is also not subject to methyl guanine transferase (MGMT) mediated resistance, as is the case with TMZ,
indicating that AG119 may be potentially useful in treating resistant gliomas.
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Background
Gliomas comprise the majority of adult primary brain
tumors diagnosed annually in the United States [1–4].
Gliomas are classified by the World Health Organization
according to their morphologic characteristics into
astrocytic, oligodendroglial, and mixed tumors [4, 5].
High grade gliomas (HGGs; grades III and IV) are the
most common primary brain tumors in adults, and their
malignant nature ranks them fourth in incidence of can-
cer death [2–4]. Approximately 15,000 patients die with
glioblastomas (GBM, glioblastoma multiforme; a grade
IV glioma) in the U.S.A. annually [1–4]. Malignant brain
tumors kill approximately 140,000 people worldwide per
year [6]. Standard treatment for GBM, which typically
involves surgical resection followed by a combination of
radiation and chemotherapy with the standard-of-care
(SOC) temozolomide (TMZ), has not substantially im-
proved overall survival (median survival remains 15 to
18 months, five-year survival rates are <10 %) [7, 8].
Prognosis is even poorer for recurrent disease, with
response rates for cytotoxic chemotherapy typically in
the range of 5 to 10 %, and 6-month progression-free
survival rates of <15 % [9, 10].
One therapeutic strategy being actively pursued for
multiple cancers is targeting angiogenesis, because
without the ability to vascularize, a tumor cannot grow
in size. Conversely, normal tissue is already vascular-
ized and is not affected by angiogenic inhibition.
Angiogenesis is greatly upregulated in HGGs com-
pared to low-grade gliomas (LGGs) [8]. Angiogenesis
is an essential process that provides excess nutrients
to developing tumors even at a very early stage [11].
In fact, assessing angiogenesis is one of the most
important criteria for grading tumors in patients [12].
In addition to cytotoxic chemotherapy, bevacizumab
(Avastin®), an anti-VEGF antibody therapeutic, is also
used to inhibit angiogenesis as a treatment for recur-
rent GBM, but it has not been found to significantly
improve the clinical outcome [7, 8].
AG119 (previously referred to as 3⋅HCl [13]) is a small
molecule discovered in our laboratory and found to pos-
sess anti-angiogenic (RTK inhibition) and antimicrotu-
bule cytotoxic activity in a single molecule [13]. It was
further found that AG119 possesses antitumor efficacy
in two flank xenograft models – human MDA-MB-435
breast (free of melanoma cross-contamination [14]) and
human U251 glioma, and anti-metastatic activity in a
mouse orthotopic breast allograft (4 T1) model, with
little systemic toxicity [13]. Due to the strong in vivo
efficacy and potent angiogenic inhibitory activity of
AG119 (decreased VEGFR2 (vascular endothelial growth
factor receptor 2) and CD31/PECAM-1 immunohisto-
chemical staining), and since we have previously shown
that this compound is not a substrate for ATP binding
cassette (ABC) transporters [13], a mechanism behind
why many drugs fail to cross the blood–brain barrier
[15], we tested AG119 as a potential anticancer therapy




Procedures for preclinical assessment of anti-cancer
therapeutics in an orthotopic GL261 mouse glioma
model were approved by the Institutional Animal Care
and Use Committees (IACUC) at the Oklahoma Med-
ical Research Foundation (OMRF) and the University
of Oklahoma Health Sciences Center (OUHSC). Anes-
thetized C57BL6 mice (Harlan Laboratories) were im-
planted with GL261 mouse glioma cells (1 × 104 cells
in 6 μL PBS) (ATCC) as previously described for other
glioma cells [16–18]. There were 5 treatment groups
(untreated, anti-VEGF antibody, anti c-Met antibody,
TMZ or AG119), which had 5–7 mice per group.
Treatments were started once tumors were 10–
20 mm3 as measured by MRI. Antibody therapies were
administered at a dose of 1 mg/kg body weight i.v. via
a tail-vein catheter every 3 days for up to 21 days [19].
TMZ and AG119 were administered at a dose of 30 mg/
kg, i.p., twice weekly for 2 weeks. AG119 was dissolved in
5 % N-methylpyrrolidine (Pharmasolve; Sigma-Aldrich),
5 % solutol-15 (BASF, Bern, Switzerland) in sterile normal
saline. TMZ was dissolved in 5 % DMSO and 5 % solutol-
15 in sterile saline. Antibody therapies (anti-c-Met
(Met (B-2): sc-8057; Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) and anti-VEGF (anti-mouse VEGF-A;
Biolegend Inc., San Diego, CA) were prepared in sterile
saline. Control untreated tumor-bearing mice received
the same solvent as for those that were treated with
AG119 (vehicle control).
MRI assessment of tumor volumes
MRI experiments were performed on a Bruker Bio-
spec 7.0 Tesla/ 30-cm horizontal-bore magnet imaging
system. Animals were immobilized with 1.5–2.5 % iso-
flurane and 0.8 L/min O2 and placed in a 72-mm
quadrature volume coil for signal transmission, and a
surface mouse-head coil was used for signal reception.
Morphological T1 and T2-weighted MRI were used to
assess tumor growth and calculate tumor volumes, as
previously described [17, 18, 20], over a 25–35 day
time period at 5–7 day intervals. Tumor volumes were
calculated from multiple MRI slice datasets. Percent
survival [Kaplan-Meier plots generated in Prism
(GraphPad Software)] were also obtained from time-
points when mice were euthanized 1–2 days prior to
expected disease-initiated deaths. All animals were hu-
manely euthanized (CO2 asphyxiation) when they met
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tumor burden criteria (tumors ≥ 150 mm3) and/or showed
signs of illness, weight loss, poor body condition, por-
phyria, hypoactivity, restlessness, aggressiveness, ataxia,
shallow, rapid and/or labored breathing, cachexia, fail-
ure to respond to stimuli, lack of inquisitiveness,
vocalization, seizures, hunched posture and ruffled fur.
Two animals died due to anesthesia complications, but
were included in the survival data.
Perfusion imaging (ASL)
Arterial spin label (ASL) perfusion images were obtained
to calculate relative cerebral blood flow (rCBF) rates in
tumors, as previously described [21]. Perfusion maps
were obtained on a single axial slice of the brain located
on the point of the rostro-caudal axis where the tumor
had the largest cross-section [21]. The imaging geometry
was a 3.5 × 3.5 mm2 slice, of 1.5 mm in thickness, with a
single shot echo-planar encoding over a 64 × 64 matrix.
An echo time of 20 ms and a repetition time of 18 s
were used. To obtain perfusion contrast, the flow al-
ternating inversion recovery scheme was used. Briefly,
inversion recovery images were acquired using a slice-
selective (SS) inversion of the same geometry as the
imaging slice or a non-selective (NS) inversion slice
concentric with the imaging slice.
Recovery curves obtained from each pixel of non-
selective (SNS(TI) =A – B • e
-TI/T1*) or selective (SSS(TI) =
A – B • e-TI/T1*), with 1/T1* = 1/T1 +CBF/λ, inversion im-
ages were numerically fitted to derive the pixelwise T1 and
T1* values, respectively [22]. The results were stored as
maps for further analysis. These longitudinal recovery
rates were then used to calculate the cerebral blood flow,
CBF (ml/(100 g · min)) on a pixelwise basis using the
following relationship: CBF = λ • [(1/T1*) – (1/T1)] [22].
The partition coefficient, λ, was scaled by assigning the
generally adopted value of 0.9 ml/g [22]. Regions of
interest (ROIs) were manually outlined around the
tumor and a copy will be positioned onto the contralateral
side of the brain for comparison purposes.
Viability assay
U251 (TMZ-sensitive; low level of methyl guanine trans-
ferase (MGMT)) and T98G (TMZ-resistant; high level
of MGMT) cells [23] (American Type Culture Collec-
tion, Manassas, VA) were maintained at Dulbecco’s min-
imal essential medium (DMEM) (Thermo Fisher
Scientific) with 10 % Cosmic Calf Serum (CCS, Hyclone,
Logan, UT) and added glutamine/pyruvate (HyClone) at
37 °C with 5 % CO2. Cells were treated with AG119 or
TMZ (Sigma, St. Louis, MO) dissolved in Opti-MEM
(Invitrogen, Carlsbad, CA) from 50 mM DMSO stock
solutions. After 4 h of treatment, 10 % CCS was added
and cells incubated for an additional 44 h. To determine
viability, PrestoBlue (Invitrogen) was added as per man-
ufacturer’s protocol and read on a microplate reader
(BioTek, Winooski, VT). IC50 values were determined by
nonlinear regression analysis in Prism 6.0 software
(GraphPad, San Diego, CA).
Statistical analyses
Statistical analyses were performed by using One-way
ANOVA with a post Tukey’s multiple comparison test
for evaluating differences in tumor volumes between
untreated and treated groups. Data is represented as
mean ± S.D., and p-values < 0.05 (*), < 0.01 (**), < 0.001
(***) were considered statistically significant. For survival
curves, statistical differences were determined using a
Log-rank (Mantel-Cox) test and a Gehan-Breslow-
Wilcoxon test.
Results
Animal survival in different treatment groups
Percent animal survival were assessed for GL261-bearing
mice that were either untreated or treated with either
AG119, TMZ or antibody therapies against c-Met or
VEGF. Percent survival of tumor-bearing mice treated
with AG119 was significantly higher (p < 0.001) compared
to untreated tumors, as depicted in Fig. 1. Compared to
UT glioma-bearing mice, TMZ, anti-c-Met or anti-VEGF
Fig. 1 Survival data for treated and untreated GL261 glioma-bearing mice. AG119 (n = 7), TMZ (n = 5), anti-c-Met antibody (n = 5), and anti-VEGF
antibody (n = 5) treated GL261 glioma-bearing mice, compared to untreated controls (UT) (n = 5). When comparing AG119 (***p < 0.001; p = 0.0003) or
TMZ (**p < 0.01; p = 0.0016) to UT, there was a significant increase in survival
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therapies all had significant increases in animal survival
(p < 0.01 for each). It is important to note that TMZ,
however, was found to have a significant increased per-
cent survival when compared to AG119 (p < 0.01).
Tumor volume determination from MR images
Morphological MRI was used to calculate tumor vol-
umes. Tumor volumes (21–31 days following intracere-
bral implantation of GL261 cells) were found to be
significantly lower for AG119-treated mice (p < 0.001)
compared to untreated controls (Fig. 2a). Other current
treatments for gliomas, which included anti-VEGF (p <
0.05) or anti-c-Met (p < 0.01) antibody therapies, or
TMZ (p < 0.05), also had significant decreases in tumor
volumes when compared to untreated tumors. Due to
the large standard deviation for the TMZ tumor
volumes, it was not possible to establish if there was a
significant difference compared to AG119, as TMZ
was found to significantly increase survival compared
to AG119 (see Fig. 1). Representative MR images of
untreated and treated mice are shown in Fig. 2b-f.


























Fig. 2 a Tumor volumes (mm3) of GL261 glioma-bearing animals either untreated (UT) or treated with anti-VEGF (n = 5) or anti-c-Met (n = 5)
antibody therapies, TMZ (n = 5), or AG119 (n = 7), as measured by MRI. There was a significant decrease in tumors treated with either AG119
(***p < 0.001; p = 0.00067), TMZ (*p < 0.05; p = 0.03392), anti-VEGF (*p < 0.05; p = 0.01540) or ant-c-Met (**p < 0.01; p = 0.00539) when compared
to untreated mice. b-f T2-weighted MR images of GL261 glioma-bearing mice. Tumors are outlined in red based on tumor boundary contrast
with ‘normal’ brain tissue. b Representative untreated mouse (vehicle control) (21 days following GL261 cell implantation). c Anti-VEGF
antibody treated mouse at 27 days after cell implantation. d Anti-c-Met antibody treated mouse at 28 days following cell implantation.
ei-v TMZ-treated mice at 28–30 days following cell implantation. fi-v AG119-treated mice at 26–29 days following cell implantation. Mice
were treated when tumor volumes were >10 mm3. Tumor volumes were measured by adding tumor areas in multiple 1 mm image slices.
Each image is obtained from different mice in each treatment group
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therapies including anti-VEGF and anti-c-Met anti-
body therapies, or TMZ, regarding tumor volumes.
Tumor perfusion as a measure of tumor-associated vascular
changes
In order to assess tumor microvasculature, tumor perfu-
sion rates were obtained from MRI perfusion maps.
Overall decreases in perfusion rates comparing tumor
to contralateral regions were obtained. Perfusion data
(Fig. 3a) indicates that both AG119 (see Fig. 3cii for an
example) and TMZ (see Fig. 3dii for an example) were
able to significantly increase perfusion rates (p < 0.05 for
both; observed as reduced decreases in perfusion rates),
compared to untreated tumors which normally have
substantially decreased perfusion rates associated with
an increased capillary bed and angiogenesis associated
with a tumor (Fig. 3bii). Both AG119 (Fig. 3a, cii) and
TMZ (Fig. 3a, dii) have a measurable anti-angiogenic
effect in GL261 gliomas in vivo, which is keeping with
the anti-angiogenic effects of TMZ in other orthotopic
glioma models [24].
Cytotoxic effect of AG119 on temozolomide
(TMZ)-resistant cells
Finally, it was determined whether AG119 retained sen-












































Fig. 3 a Measured decreases in perfusion rates (ml/100 g x min) in untreated, TMZ- or AG119-treated GL261 mouse gliomas. Perfusion rates were
measured using an arterial spin label perfusion MRI method, and relative decreases in tumors were obtained compared to the contralateral side.
There were significant increases in tumor perfusion rates in both AG119 and TMZ-treated tumors (*p < 0.05), compared to untreated tumors,
which had substantially decreased perfusion rates. b-d Perfusion MR images of untreated (b), TMZ (c), and AG119-treated (d) GL261 glioma-bearing
mice. T2-weighted morphological images are in the top panels (i), and perfusion maps are in the bottom panels (ii). Dark region in panel Bii
depicts decreased perfusion rates in an untreated tumor, which is not as severe in treated tumors (panels cii and dii). Tumors are outlined in red
Towner et al. BMC Cancer  (2015) 15:522 Page 5 of 8
overexpress O6-methylguanine-DNA-methyltransferase
(MGMT), a DNA repair enzyme conferring resistance
to a number of alkylating agents, including TMZ [25].
When comparing drug sensitivity of T98G cells to a
relatively drug sensitive glioma line, U251, it was found
that as expected the T98G cells were significantly less
sensitive to TMZ (Fig. 4). It was also found that TMZ-
resistant T98G cells were sensitive to AG119, as were
the TMZ-sensitive U251 cells (Fig. 4; IC50 comparison).
Discussion
It is well known that GL261 is a syngeneic mouse model
of HHG in C57BL/6 mice with several morphological,
pathological and genetic similarities to human GBM
[26]. It has also been previously reported that the blood-
tumor-barrier in GL261 gliomas are quite “leaky” which
allows the penetration of various therapeutic compounds
[27], as well as molecular targeting agents which we
have reported on [28]. In this work we demonstrate in
the GL261 glioma model that AG119, a small molecule
with combined anti-angiogenic and antimicrotubule
activity [13], results in a significant increase in animal
percent survival (p < 0.001), as well as a significant de-
crease in GL261 HGG tumor growth in vivo (p < 0.001),
compared to untreated tumors. AG119 was also found
to be similar to the standard-of-care (SOC) TMZ, and
relatively new anti-VEGF and anti-c-Met antibody tar-
geted therapies. It should be noted that antibody therap-
ies in this study were not optimized, i.e. doses used
elicited therapeutic responses, but did not necessarily
induce tumor regression [29]. Also of note, the survival
data included anesthesia-related deaths for the AG119
treatment group which may not properly reflect the ac-
tual survival times for this treatment group, and should
be repeated in future studies. Regardless, this proof-of-
concept study does indicate that AG119 has anti-cancer
activity in a pre-clinical glioma model.
AG119 was also found to significantly decrease tumor
perfusion rates as well as TMZ (both p < 0.05, when com-
pared to untreated tumors). Perfusion rates decrease in
HGG, such as the GL261 model, as a result of the disorga-
nized capillary architecture from vasculature associated
with angiogenesis [22]. This is in keeping with previous
findings that AG119 possessed inhibition of VEGFR2 kin-
ase and anti-angiogenic activity in the chicken embryo
chorioallantoic membrane (CAM) assay [13].
These data are encouraging because currently ap-
proved active antimicrotubule agents such as the taxanes
do not readily cross the blood–brain barrier and are not
useful for central nervous system (CNS) tumors, even
though gliomas show taxane sensitivity in culture [30].
We have also previously shown that AG119 is not sub-
ject to resistance mechanisms common to other antimi-
crotubule agents (beta-III tubulin over-expression [25],
P-glycoprotein) in tumors such as gliomas, suggesting
that this agent may have a therapeutic advantage over
current agents [13, 31]. This work suggests that AG119
is also not subject to MGMT mediated resistance, as is
the case with TMZ. A study to further explore this idea
would be a comparison of AG119 sensitivity in parental
U251 cells as compared to T98G cells with MGMT
knocked out. Thus AG119 may be useful in treating his-
torically resistant gliomas.
Conclusions
Taken together, in this study we demonstrate that AG119,
a small molecule with combined anti-angiogenic and anti-
microtubule activity, can significantly increase animal per-
cent survival, significantly decrease GL261 HGG tumor
growth, significantly decrease tumor vascularity, compared
to untreated tumors, and suggests that this compound is
also not subject to MGMT mediated resistance. These
data support further exploration of the anticancer activity
AG119 in HGG, perhaps together with SOC and/or newer
agents like the c-Met inhibitors. In fact, it has been re-
cently shown that combining a VEGF inhibitor (AG119
inhibits VEGFR2 kinase) with a c-Met inhibitor may
have therapeutic advantage in vivo [32].
Fig. 4 Cytotoxic effect of AG119 on temozolomide (TMZ)-resistant
cells. Cells, U251 (TMZ-sensitive; MGMT−) and T98G (TMZ-resistant;
MGMT+), were treated with AG119 or TMZ for 48 h and viability
determined with Presto Blue. Data are mean IC50 values (μM) ± SEM,
n = 4–9 independent experiments
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